

# MARKET REPORT



## PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

DelveInsight's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 47+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight's Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 36+ active companies involved in the therapeutic development of the products.

## Scope

- The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for PD and PD-L1 inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

## Reasons to Buy

- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.

- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario

Current Prominent Research Areas and Key Players

Collaborations details and Deal values

Technologies and Targeted antigens

Pipeline product profiles CAR-T Technologies and Targeted Antigens

Licensing opportunities

Market Drivers and Barriers

SWOT Analysis

## Additional Details

**Publisher** : Delve Insight

**Reference** : DISR0001

**Number of Pages** : 311

**Report Format** : PDF

**Publisher Information** :

The advertisement features a person in a white lab coat holding a report cover. The report cover displays the DelveInsight logo, a cityscape, and the BioPortfolio title. The background is a blurred laboratory setting with a hand in a blue glove holding a pipette.

**DELVEINSIGHT**  
INSIGHTS DRUGS PATENTS & DATA

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

# Table Of Contents for PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

- IntroductionExecutive SummaryProgrammed Death 1 (PD-1)Programmed Death Ligand 1 (PD-L1)Role of PD-1 and PD-L1 pathwaysMOA of PD-1 and PD-L1 inhibitorsSignificance of PD-1 and PD-L1 inhibitorsPD-1 and PD-L1 Active Therapy Areas & EpidemiologyMetastatic Renal Cell CarcinomaSquamous Cell Carcinomas of the Head and NeckMetastatic Colorectal CancerNon-Small Cell lung cancerBiomarkers - PD-1 and PD-L1 inhibitorsMarket OverviewComparative Analysis of Pipeline &Marketed DrugsMarketed Product of PD-1 and PD-L1 drugs -OverviewMarketed Drug Candidate ProfilesPembrolizumabNivolumabAtezolizumabMarketed Drugs SalesDetails of Patent Expiry of Marketed DrugsCurrent and Future Market for PD and PD-L1 inhibitorsChallenges and Barriers associated with use of PD and PD-L1 inhibitorsPD-1/PD-L1Combinations Creating BoomPipeline TherapeuticsAn overview of pipeline productsPipeline Therapeutics OverviewTherapeutics under Development by MOATherapeutics under Development by CompaniesLast Stage Products (Phase III and Filed)Comparative AnalysisMid Stage Products (Phase II)Comparative AnalysisEarly Stage Products (Phase I and IND)Comparative AnalysisPre-Clinical and Discovery ProductsComparative AnalysisUnknown Stages MoleculesTherapeutic Assessment of pipelineTherapeutics under Development by Product TypeTherapeutics under Development by Phase for MonotherapyTherapeutics under Development by Phase for Combination therapyTherapeutics under Development by Molecule TypeAssessment by Stage and Molecule TypeTherapeutics under Development by Route of AdministrationAssessment by Stage and Route of AdministrationDormant ProductsComparative AnalysisSWOT AnalysisAppendixMethodologyConsulting ServicesAbout DelveInsightContact UsDisclaimer

# List Of Tables in PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

Table 1: Marketed and Pipeline drugs for PD-1 and PD-L1 Drugs, 2017

Table 2: PD-1 Marketed Drugs, 2017

Table 3: Sales of Marketed drugs, 2017

Table 4: Details of patent expiry of marketed molecules, 2017

Table 5: Merck's drug- Keytruda (Pembrolizumab) Partners for Combination Therapies

Table 6: Bristol Myers Squibb's drug- Opdivo (nivolumab) Partners for Combination Therapies

Table 7: Roche's drug- Atezolizumab (MPDL-3280A) Partners for Combination Therapies

Table 8: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2017

Table 9: Comparative Table for PD-1 and PD-L1 inhibitors Drugs, 2017

Table 10: Number of Products under Development by Companies, 2017

Table 11: Last Stage Products (Phase III and Filed), 2017

Table 12: Mid Stage Products (Phase II), 2017

Table 13: Early Stage Products (Phase I and IND), 2017

Table 14: Pre-Clinical and Discovery Products, 2017

Table 15: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2017

Table 16: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2017

Table 17: Number of Combination therapy Products for PD-1 and PD-L1 inhibitors, 2017

Table 18: Number of Products under Development by Molecule Type, 2017

Table 19: Assessment by Stage and Molecule Type, 2017

Table 20: Number of Products under Development by Route of Administration, 2017

Table 21: Assessment by Stage and Route Of Administration, 2017

Table 22: Dormant Products, 2017

# List Of Figures, Charts and Diagrams in PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

Figure 1: Marketed and Pipeline drugs for PD-1 and PD-L1 Drugs, 2017

Figure 2: Sales of marketed drugs, 2017

Figure 3: Details of patent expiry of marketed molecules, 2017

Figure 4: Number of Products under Development for PD-1 and PD-L1 inhibitors Drugs, 2017

Figure 5: Comparative Graph for PD-1 and PD-L1 inhibitors Drugs, 2017

Figure 6: Last Stage Products (Phase III), 2017

Figure 7: Mid Stage Products (Phase II), 2017

Figure 8: Early Stage Products (Phase I and IND), 2017

Figure 9: Pre-Clinical and Discovery Products, 2017

Figure 10: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2017

Figure 11: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2017

Figure 12: Number of Combination therapy Products for PD-1 and PD-L1 inhibitors, 2017

Figure 13: Percentage of pipeline drugs by Molecule Type (%), 2017

Figure 14: Assessment by Stage and Molecule Type, 2017

Figure 15: Percentage of pipeline drugs by Route of Administration(%), 2017

Figure 16: Assessment by Stage and Route of Administration, 2017

Figure 17: Dormant Products, 2017



# How to Buy...

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/105553>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$2950** | Single User Price
- \$5900** | Site License Price
- \$8850** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.